Financial Performance - Revenue for Q3 2025 totaled $146,000, a 15.9% increase from $126,000 in Q3 2024[6] - Gross loss for Q3 2025 was $145,000, compared to a gross profit of $44,000 in Q3 2024, primarily due to $230,000 in inventory reserves[6] - Operating expenses increased to $2.3 million in Q3 2025 from $1.5 million in Q3 2024, attributed to the addition of the biopharma business and increased corporate costs[6] - Net loss for Q3 2025 was $2.6 million, compared to a net loss of $1.4 million in Q3 2024[9] - Tivic's gross margin, excluding inventory reserves, was 42% in Q3 2025, compared to 35% in Q3 2024[6] Cash Position - Cash and cash equivalents as of September 30, 2025, were $3.5 million, up from $2.0 million at December 31, 2024[9] Business Development - Tivic completed the transfer of two INDs from Statera Biopharma, enabling clinical trials for Entolimod in neutropenia and cancer-related conditions[6] - The company successfully completed cell line verification, a key step for cGMP manufacturing, necessary for filing a biologics license application with the FDA[6] - The company executed the write-down of ClearUP inventory, resulting in $230,000 of cost of goods sold and $117,000 of other expenses[9] - The company is advancing discussions for deploying Entolimod as a military countermeasure and stockpile drug[6]

Financial Performance - Revenue for the three months ended September 30, 2025 decreased by 97.6% to $72,377 compared to $3,052,727 for the same period in 2024, primarily due to cash constraints limiting inventory purchases [296] - Gross profit for the three months ended September 30, 2025 was $426, resulting in a gross margin of 0.6%, down from 7.5% in the same period of 2024 [299] - Revenue for the nine months ended September 30, 2025 decreased 80.8% to $1,663,205 compared to $8,662,414 for the same period in 2024 [310] - Gross profit was $204,684 for the nine months ended September 30, 2025, down from $992,650 in 2024, while gross margin increased to 12.3% from 11.5% [313] - Net loss for the three months ended September 30, 2025 was $2,170,789, a decrease of $579,547 from the net loss of $2,750,336 for the same period in 2024 [307] - Net loss for the nine months ended September 30, 2025 was $5,961,537, a decrease of $863,924 from the net loss of $6,825,461 in 2024 [322] Expenses and Costs - Selling, general and administrative expenses decreased by 44.9% to $1,205,125 for the three months ended September 30, 2025, compared to $2,186,953 for the same period in 2024 [300] - Operating expenses decreased 27.0% to $3,849,952 in 2025, primarily due to a 32.0% reduction in selling, general and administrative expenses [314] - Provision for credit losses increased by 246.5% to $126,824 for the three months ended September 30, 2025, compared to $36,597 for the same period in 2024 [301] - Provision for credit losses increased 401.9% to $306,091 in 2025, reflecting higher estimated credit risk associated with outstanding receivables [316] Cash Flow and Financing - Cash and cash equivalents at the end of the period were $61,450, compared to $40,114 at the end of September 30, 2024 [333] - Net cash used in operating activities was approximately $1.8 million for the nine months ended September 30, 2025, down from $3.2 million in 2024 [334] - The company has a $20 million equity financing program declared effective by the SEC to address liquidity needs [324] - The company has entered into a securities purchase agreement for $2 million with Y.K. Capital Management, Inc., with an initial payment of $500,000 received [327] - Net cash provided by financing activities for the nine months ended September 30, 2025, was approximately $2.3 million, driven by proceeds from Series A and D preferred stock, warrant exercises, and convertible notes borrowing [338] - In comparison, net cash provided by financing activities for the nine months ended September 30, 2024, was approximately $3.0 million, mainly from short-term loans and public offerings [339] Business Development and Strategy - The company plans to enter the electric vehicle market by distributing medium-sized trucks in Latin America and developing indoor growing systems within these trucks [280] - The company is investing in Future Tech Inc., a Bitcoin mining and data center business, and plans to enter the field of Digital Treasury Management focusing on XRP [280] - The company has added new products including organic and non-organic fertilizers and dehumidifiers to enhance its offerings [283] - The company is developing proprietary "all in one" automated and robotic indoor growing systems currently in design and testing phases [286] - The company entered into a strategic cooperation agreement with Sinoinnovo Technology for sourcing grow light systems for distribution in the U.S. and Europe [289] Customer Metrics - The number of customers decreased from 114 in 2024 to 68 in 2025, with average revenue per customer dropping from $75,986 to $24,459 [311] Accounting and Valuation - The company follows ASC 606 for revenue recognition, recognizing revenue upon satisfying performance obligations related to product sales [344] - Accounts receivable are stated at expected collectible amounts, with an allowance for expected credit losses based on historical and forecasted conditions [354] - Inventory is valued at the lower of cost and net realizable value, using the weighted average costing method, and is regularly reviewed for obsolescence [355] - The company reviews long-lived assets for impairment annually and determined no impairment as of September 30, 2025, with estimated disposal values exceeding carrying values [357] Non-Cash Transactions - Non-cash transactions included asset acquisitions via preferred stock and convertible note issuances totaling approximately $12.8 million related to Zak Properties, LLC [340] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements that could materially affect its financial condition or results of operations [342]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-42889 Commercial Bancgroup, Inc. (Exact Name of Registrant as Specified in its Charter) | Tennessee | 62-1039469 | | --- | --- | | (State or other jurisdiction ...

Financial Performance - For the three months ended September 30, 2025, total operating expenses were $1,873,943, a decrease of approximately 10% from $2,083,192 in the same period of 2024[97]. - The net loss for the three months ended September 30, 2025, was $1,873,669, compared to a net loss of $2,084,032 for the same period in 2024, reflecting an improvement of approximately 10%[97]. - The company incurred a loss from operations of $6,580,525 for the nine months ended September 30, 2025, contributing to an accumulated deficit of $112,652,321[104]. - Net cash used in operating activities was $6,356,680 for the nine months ended September 30, 2025, compared to $6,414,590 in 2024[108]. - Cash on hand as of September 30, 2025, was $3,757,594, which is insufficient to meet operating cash needs for the next 12 months[105]. - Management has substantial doubt about the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements[106]. Expenses - General and administrative expenses increased by $235,496, or 20%, to $1,431,157 for the three months ended September 30, 2025, primarily due to higher marketing and legal expenses[98]. - General and administrative expenses decreased to $4,010,313 for the nine months ended September 30, 2025, from $4,329,565 for the same period in 2024, a decrease of 7%[101]. - Research and development expenses decreased by $400,300, or approximately 50%, to $402,417 for the three months ended September 30, 2025, driven by reduced costs in various areas[99]. - Research and development expenses increased to $2,408,839 for the nine months ended September 30, 2025, from $1,873,873 in 2024, an increase of approximately 29%[102]. - The Company experienced a significant decrease in depreciation and amortization expense, which fell by approximately 52% to $40,369 for the three months ended September 30, 2025, due to full amortization of intangible assets[100]. - Depreciation and amortization expense decreased to $161,373 for the nine months ended September 30, 2025, from $255,002 in 2024, a decrease of approximately 37%[103]. Equity and Financing - The Company reported stockholders' equity of $3,456,176 as of September 30, 2025, regaining compliance with Nasdaq Listing Rule 5550(b)(1)[95]. - The Company entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell shares of Common Stock with an aggregate offering price of up to $1,854,151, raising net cash proceeds of $1,636,799 as of September 30, 2025[91]. - Net cash provided by financing activities was $7,890,361 for the nine months ended September 30, 2025, compared to $7,210,386 in 2024[111]. - The company has not generated revenue since inception and has relied on debt and equity financing to fund operations[104]. Compliance and Risks - The Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a stock price below $1.00 but subsequently regained compliance following a 1-for-12 reverse stock split[96]. - The company is subject to foreign currency exchange rate risk due to transactions in Canadian and Australian dollars[116]. Product Development - The Company plans to advance its lead drug candidate EB-003 through preclinical studies and aims to initiate first-in-human studies to assess safety and tolerability[88]. - The EVM401 Series was unveiled on February 25, 2025, to broaden the pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders[90].

Revenue and Financial Performance - Revenue for Q3 2025 totaled approximately $7.3 million, with $5.1 million from XpresSpa, $1.7 million from XpresCheck, and $0.5 million from Naples Wax Center[5][13]. - Net loss attributable to XWELL for Q3 2025 was approximately $0.7 million, a significant reduction from approximately $4.8 million in the comparable prior year period[14]. - Total operating expenses for Q3 2025 were approximately $2.3 million, down from approximately $6.8 million in the prior year[13]. Cost Management - Cost of sales decreased approximately 8% from Q3 2024, totaling around $5.9 million for Q3 2025 compared to $6.4 million in the prior year[5][13]. - General and administrative expenses, excluding one-time credits, decreased approximately 32% from Q3 2024[5]. - The Company streamlined its cost structure, reducing approximately $2.4 million in annualized staffing costs[6]. Expansion and Partnerships - XWELL expanded its partnership with Priority Pass to key international airports across the Middle East and Europe, enhancing access to wellness offerings for travelers[5][7]. - New wellness centers opened in Florida, including locations at Bloomingdale Square and Waterford Lakes, with a Penn Station location set to open in mid-November[5][9]. - XWELL continues to pursue opportunities for potential acquisitions to extend its reach into the broader wellness consumer landscape[9]. Cash Position - As of September 30, 2025, the Company had approximately $4.0 million in cash and cash equivalents and no long-term debt[12].

Financial Performance - Net sales for the three months ended September 30, 2025, were $740,000, while the company had no revenue in the comparable periods of 2024 [78]. - The net loss for the three months ended September 30, 2025, was $1,018,768, compared to a net loss of $428,906 in the Successor 2024 Period [78]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $631,875, including a net loss of $2,218,121 [88]. Expenses - SG&A expenses increased to $999,923 for the three months ended September 30, 2025, compared to $156,091 in the Predecessor QTD Period, primarily due to shares issued for consulting and investor relations services [79]. - SG&A expenses for the nine months ended September 30, 2025, totaled $2,200,504, significantly higher than $654,573 in the Predecessor YTD Period [83]. - Interest expense for the nine months ended September 30, 2025, was $19,720, compared to $67 in the Predecessor YTD Period, primarily due to a new term loan [84]. Liquidity and Funding - As of September 30, 2025, the company had $16,123 in cash and cash equivalents and a borrowing capacity of $80,000 under a Term Loan agreement [85]. - The company expects to raise approximately $4.0 million through a public offering to support liquidity and product development over the next twelve months [86]. Product Development - The company is still in the process of developing and commercializing its products, resulting in inconsequential net sales and cost of sales for both the three and nine months ended September 30, 2025 [78][82]. - The company is taking steps to establish formal processes and controls for disclosure and internal controls as it matures as a public company [102].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code: (919) 313-9633 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 Lite Strategy, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

Financial Performance - For the three months ended September 30, 2025, net sales were $2,011,556, a decrease of 21% compared to $2,542,251 for the same period in 2024[18]. - Gross profit for the nine months ended September 30, 2025, was $2,860,840, down 30% from $4,086,311 in the same period of 2024[18]. - The net loss for the nine months ended September 30, 2025, was $1,943,457, compared to a net loss of $1,221,030 for the same period in 2024, indicating a deterioration of 59%[18]. - For the three months ended September 30, 2025, the company reported a net loss of $450,348, compared to a net income of $58,962 for the same period in 2024[55]. - Total revenue for the three months ended September 30, 2025, was $2,012,000, a decrease of 20.8% from $2,542,000 in the same period of 2024[63]. - For the nine months ended September 30, 2025, total revenue was $4,619,000, a decline of 30.6% from $6,670,000 in the same period of 2024[65]. Assets and Liabilities - Total current assets decreased to $5,030,309 as of September 30, 2025, from $6,493,113 at December 31, 2024, representing a decline of approximately 22%[15]. - Total liabilities increased to $5,838,709 as of September 30, 2025, compared to $5,594,799 at December 31, 2024, reflecting a rise of about 4%[15]. - Total shareholders' equity decreased to $2,206,482 as of September 30, 2025, from $4,098,939 at December 31, 2024, a decline of about 46%[15]. - Cash and cash equivalents decreased to $490,022 as of September 30, 2025, from $664,879 at December 31, 2024, a decline of approximately 26%[15]. Operating Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $5,069,409, slightly up from $5,041,873 in the same period of 2024[18]. - The company’s cash paid for interest increased to $309,314 for the nine months ended September 30, 2025, compared to $222,000 for the same period in 2024, indicating higher financing costs[23]. - General and administrative expenses for the three months ended September 30, 2025, were $1,072,000, an increase of $162,000 or 18% compared to the same period in 2024[198]. Revenue Breakdown - Revenue from the SteraMist product line for the three months ended September 30, 2025, was $1,603,000, down from $1,766,000 in 2024[63]. - The company recognized service and training revenue of $409,000 for the three months ended September 30, 2025, down from $776,000 in 2024[64]. - Domestic revenue for the three months ended September 30, 2025, was $1,280,000, a decrease of $606,000 or 32% compared to the same period in 2024[188]. - International revenue for the three months ended September 30, 2025, was $732,000, an increase of $76,000 or 12% compared to the same period in 2024[189]. Cash Flow and Financing - Net cash used in operating activities was $(576,780) for the nine months ended September 30, 2025, a significant improvement compared to $(1,452,862) for the same period in 2024[23]. - Cash provided by financing activities increased significantly to $535,000 for the nine months ended September 30, 2025, compared to $28,000 in the same period of 2024[211]. - The company plans to fund ongoing activities through current cash, cash generated from operations, and raising additional capital, though there is no assurance of success in raising such capital[85]. Inventory and Credit Losses - The allowance for credit losses increased to $2,229,977 as of September 30, 2025, up from $1,494,347 at December 31, 2024, indicating a rise in expected credit losses[39]. - The reserve for obsolete inventory was $868,000 as of September 30, 2025, down from $1,100,000 as of December 31, 2024, indicating improved inventory management[43]. - The company reported a credit loss expense of $197,639 for the nine months ended September 30, 2025, compared to $1,050,543 for the same period in 2024, showing a decrease in credit loss expense[39]. Strategic Initiatives - The company successfully completed multiple high-profile installations of its iHP technology, including at NASA's Johnson Space Center and Virginia Commonwealth University, demonstrating its adaptability in high-containment environments[152]. - The FDA's final rule broadening the use of hydrogen peroxide as a direct food additive is expected to positively impact the company's positioning in the food safety market, particularly in the ready-to-eat segment[157]. - The company is experiencing revenue growth among distributors and international partners, particularly in Europe, as it works towards finalizing regulatory approvals in the EU and UK[155]. Management and Governance - The company appointed a new Chief Financial Officer with an annual base salary of $230,000 and eligibility for a bonus of up to 40% of the base salary[122]. - Management is implementing measures to improve financial results and cash flows, including optimizing product mix and expanding recurring solution sales, to support liquidity needs through 2025[212].